WHO HPV LabNet Global Reference Laboratory at Department of Clinical Microbiology, University Hospital, Malmö,
Clin Exp Immunol. 2011 Jan;163(1):17-25. doi: 10.1111/j.1365-2249.2010.04268.x. Epub 2010 Nov 9.
Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most cost-effective strategies for cancer control.
持续性感染致癌型人乳头瘤病毒（HPV）是宫颈癌发展的必要病因。此外，HPV 主要为 16 型和较少程度的 18 型，与不同比例的其他肛门生殖器癌症（外阴、阴道、阴茎、肛门）以及身体其他部位的癌症（口咽、喉、结膜）有因果关系。HPV 6 型和 11 型引起大多数生殖器疣和复发性呼吸道乳头瘤病。已开发出有效的预防性疫苗。在这篇综述中，我们简要讨论 HPV 感染的免疫学方面以及 HPV 疫苗接种试验的结果。国际标准化监测和评估预防性 HPV 疫苗接种计划对于制定最具成本效益的癌症控制策略至关重要。
